Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of GC012F in Relapsed/Refractory Multiple Myeloma
NCT05412329Phase 1Unknown
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Jun 2022
- Primary completion
- Jun 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC012 in multiple myeloma (MM), sponsored by Shanghai Changzheng Hospital. Primary endpoints: Dose Limiting Toxicity at 21 days and Adverse Events at 48 weeks. Status: unknown.
02
Drugs
GC012
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05412329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05412329.